294 related articles for article (PubMed ID: 18932252)
1. The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.
Murphy CD; Lee JM; Drohan B; Euhus DM; Kopans DB; Gadd MA; Rafferty EA; Specht MC; Smith BL; Hughes KS
Cancer; 2008 Dec; 113(11):3116-20. PubMed ID: 18932252
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.
Le-Petross HT; Whitman GJ; Atchley DP; Yuan Y; Gutierrez-Barrera A; Hortobagyi GN; Litton JK; Arun BK
Cancer; 2011 Sep; 117(17):3900-7. PubMed ID: 21365619
[TBL] [Abstract][Full Text] [Related]
4. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
Moyer VA;
Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
[TBL] [Abstract][Full Text] [Related]
5. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Warner E; Plewes DB; Hill KA; Causer PA; Zubovits JT; Jong RA; Cutrara MR; DeBoer G; Yaffe MJ; Messner SJ; Meschino WS; Piron CA; Narod SA
JAMA; 2004 Sep; 292(11):1317-25. PubMed ID: 15367553
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of screening with annual magnetic resonance imaging and mammography: results of the initial screen from the ontario high risk breast screening program.
Chiarelli AM; Prummel MV; Muradali D; Majpruz V; Horgan M; Carroll JC; Eisen A; Meschino WS; Shumak RS; Warner E; Rabeneck L
J Clin Oncol; 2014 Jul; 32(21):2224-30. PubMed ID: 24934793
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer screening of pregnant and breastfeeding women with BRCA mutations.
Carmichael H; Matsen C; Freer P; Kohlmann W; Stein M; Buys SS; Colonna S
Breast Cancer Res Treat; 2017 Apr; 162(2):225-230. PubMed ID: 28138892
[TBL] [Abstract][Full Text] [Related]
10. Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.
Hartman AR; Daniel BL; Kurian AW; Mills MA; Nowels KW; Dirbas FM; Kingham KE; Chun NM; Herfkens RJ; Ford JM; Plevritis SK
Cancer; 2004 Feb; 100(3):479-89. PubMed ID: 14745863
[TBL] [Abstract][Full Text] [Related]
11. BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing.
Mitri ZI; Jackson M; Garby C; Song J; Giordano SH; Hortobágyi GN; Singletary CN; Hashmi SS; Arun BK; Litton JK
Oncologist; 2015 Jun; 20(6):593-7. PubMed ID: 25948675
[TBL] [Abstract][Full Text] [Related]
12. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
Calderon-Margalit R; Paltiel O
Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
[TBL] [Abstract][Full Text] [Related]
13. An alternative approach to selecting patients for high-risk screening with breast MRI.
Hollingsworth AB; Stough RG
Breast J; 2014; 20(2):192-7. PubMed ID: 24387050
[TBL] [Abstract][Full Text] [Related]
14. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
[TBL] [Abstract][Full Text] [Related]
15. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
Hoskins KF; Zwaagstra A; Ranz M
Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460
[TBL] [Abstract][Full Text] [Related]
16. Increased Identification of Candidates for High-Risk Breast Cancer Screening Through Expanded Genetic Testing.
Rosenthal ET; Evans B; Kidd J; Brown K; Gorringe H; van Orman M; Manley S
J Am Coll Radiol; 2017 Apr; 14(4):561-568. PubMed ID: 28011157
[TBL] [Abstract][Full Text] [Related]
17. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
[TBL] [Abstract][Full Text] [Related]
18. The problems with risk selection; scientific and psychosocial aspects.
Hartman AR
Recent Results Cancer Res; 2005; 166():125-44. PubMed ID: 15648188
[TBL] [Abstract][Full Text] [Related]
19. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.
Metcalfe KA; Poll A; Royer R; Llacuachaqui M; Tulman A; Sun P; Narod SA
J Clin Oncol; 2010 Jan; 28(3):387-91. PubMed ID: 20008623
[TBL] [Abstract][Full Text] [Related]
20. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
